228 related articles for article (PubMed ID: 23942775)
1. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Kim HS; Kim HJ; Kim SY; Kim TY; Lee KW; Baek SK; Kim TY; Ryu MH; Nam BH; Zang DY
Ann Oncol; 2013 Nov; 24(11):2850-4. PubMed ID: 23942775
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced gastric cancer.
Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
[TBL] [Abstract][Full Text] [Related]
4. Palliative chemotherapy for advanced gastric cancer.
Wöhrer SS; Raderer M; Hejna M
Ann Oncol; 2004 Nov; 15(11):1585-95. PubMed ID: 15520058
[TBL] [Abstract][Full Text] [Related]
5. [Clinical development of chemotherapy for advanced gastric cancer].
Sato A; Matsukawa M
Nihon Shokakibyo Gakkai Zasshi; 2007 Feb; 104(2):186-93. PubMed ID: 17283412
[No Abstract] [Full Text] [Related]
6. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis.
Cho YH; Yoon SY; Kim SN
Cancer Res Treat; 2017 Jan; 49(1):255-262. PubMed ID: 27188198
[TBL] [Abstract][Full Text] [Related]
8. [Progress in chemotherapy for advanced gastric cancer].
Xu RH; Teng KY
Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
[TBL] [Abstract][Full Text] [Related]
9. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Takashima A; Boku N; Kato K; Nakamura K; Mizusawa J; Fukuda H; Shirao K; Shimada Y; Ohtsu A
Gastric Cancer; 2014; 17(3):522-8. PubMed ID: 24162387
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials.
Zeng C; Zhou H; Wei Y; Wang L; Xie H; Yao W
Chin Med J (Engl); 2014; 127(5):951-6. PubMed ID: 24571893
[TBL] [Abstract][Full Text] [Related]
11. Second-line chemotherapy for advanced gastric cancer in Korea.
Baek SK; Kim SY; Jeong JH; Cho KS; Yoon HJ
Gastric Cancer; 2012 Oct; 15(4):345-54. PubMed ID: 22410800
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Roy AC; Park SR; Cunningham D; Kang YK; Chao Y; Chen LT; Rees C; Lim HY; Tabernero J; Ramos FJ; Kujundzic M; Cardic MB; Yeh CG; de Gramont A
Ann Oncol; 2013 Jun; 24(6):1567-73. PubMed ID: 23406728
[TBL] [Abstract][Full Text] [Related]
13. Gastric cancer. Treatment of advanced disease and new drugs.
Caponigro F; Facchini G; Nasti G; Iaffaioli RV
Front Biosci; 2005 Sep; 10():3122-6. PubMed ID: 15970566
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K
Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718
[TBL] [Abstract][Full Text] [Related]
15. Experience with docetaxel in the treatment of gastric cancer.
Philip PA
Semin Oncol; 2005 Apr; 32(2 Suppl 4):S24-38. PubMed ID: 16015552
[TBL] [Abstract][Full Text] [Related]
16. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature.
Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RM; van Oijen MG; van Laarhoven HW
Cancer Metastasis Rev; 2016 Sep; 35(3):439-56. PubMed ID: 27417221
[TBL] [Abstract][Full Text] [Related]
17. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.
Wang DL; Gu DY; Huang HY; Xu Z; Chen JF
World J Gastroenterol; 2010 Dec; 16(46):5889-94. PubMed ID: 21155012
[TBL] [Abstract][Full Text] [Related]
19. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Gubanski M; Glimelius B; Lind PA
Med Oncol; 2014 Apr; 31(4):906. PubMed ID: 24627237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
